Development of a new antioxidant therapy for sepsis using DHLH-Zn, a novel alpha-lipoic acid

• Project/Area Number: 23792076
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Emergency medicine
• Research Institution: Oita University
• Principal Investigator: KOGA HIRONORI 大分大学, 医学部, 助教 (50468013)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: 抗酸化 / 敗血症 / ラジカル / 酸化ストレス

Research Abstract

We investigated whether Sodium Zinc Histidine Dithiooctanamide (DHLH-Zn), a novel alpha-lipoic acid derivative, had therapeutic effect against sepsis. The results of the present study indicated that DHLH-Zn ameliorated sepsis-induced organ damage by suppression of oxidative stress in rat model. In addition, we tried to clarify the mechanism of antioxidative effect. We attempted to establish the assessment method of oxidative steress in some biotic samples with the use of electron spin resonance (ESR) apparatus. It was hard to measure the oxidative steress directly because of various interfering factors in samples, however, we improved the accuracy of measurement after careful consideration.